Type of information: Publication of results in a medical journal
Announcement: publication of results in Neurotherapeutics
Product: gene therapy based on E2F4DN
Action mechanism: gene therapy. This gene therapy is based on E2F4DN, a modified variant of E2F4, a crucial protein for neuronal function. This variant cannot be phosphorylated. The blocking of this phosphorylation prevents the start of neuronal tetraploidy, restoring homeostasis and neuronal function in the brain.
Disease: Alzheimer's disease
Therapeutic area: Neurodegenerative diseases
First Spanish biotech company accelerated by the Johnson & Johnson European Innovation Center, Tetraneuron (www.tetraneuron.com) has been developing for the last 10 years an advanced therapy for Alzheimer’s disease through a therapeutic approach focused on E2F4, a protein involved in the origin of the pathogenesis mechanism of this complicated disease. With encouraging preclinical results in AD model mice with an aggravated phenotype of the disease, the company is betting on a multifactorial approach to Alzheimer’s through a gene therapy that is expected to slow the progression of this devastating disease that currently affects more than 50 million people worldwide. Unlike other strategies, Tetraneuron provides a totally disruptive vision, addressing the global causes of the pathology.
The progress of gene therapy, currently under development, is evident in some recent success stories and opens a new horizon to the possibility of curing diseases for which until now there were only treatments aimed at palliating their symptoms. In this line, Tetraneuron is also taking its vision to the development of innovative products for other neurodegenerative diseases.